Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VEFNY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
US20250000991A1 Ab2 ADC
|
|||||
| Synonyms |
Ab2 ADC
Click to Show/Hide
|
|||||
| Organization |
Eli Lilly and Company, Indianapolis, IN (US)
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1
|
|||||
| Structure |
|
|||||
| Antibody Name |
Ab2
|
Antibody Info | ||||
| Antigen Name |
Nectin-4 (NECTIN4)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
US20250000991A1 Ab1 ADC Linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.0836 nM | High Nectin-4 expression (Nectin-4 +++) | ||
| Method Description |
Ab7 ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells ;and with a DAR of 8
|
||||
| In Vitro Model | Bladder carcinoma | T24 mScarlet clone 5 nectin-4 negative cells | CVCL_0554 | ||